Disease activity assessment in LVV lacks validated scoring systems. PET/CT might be the imaging biomarker that is needed. PETVAS has shown promising results in recent studies. The current study assessed whether PETVAS can discriminate between clinically active and inactive LVV (both GCA and TAK) in a single-centre cohort study. LVV patients (n=100) were followed from 2007 until 2020 and received complete assessments (clinical, laboratory, imaging) at baseline, annually, and when relapse was suspected. PETVAS was calculated for each PET/CT scan and compared to the clinical examination of disease activity status.
Dr Elena Galli (University of Modena and Reggio Emilia, Italy) presented the results. Logistic regression analysis demonstrated that higher PETVAS scores were associated with clinically active LVV (OR 1.15; P<0.0001). This result was consistent in the GCA (OR 1.12; P<0.0001) and TAK (OR 1.22; P<0.0001) subgroups. The computed ROC curves demonstrated acceptable predictive values in the total population (AUC 0.73) and in the GCA (AUC 0.70) and TAK (AUC 0.79) subgroups. Nevertheless, higher PETVAS scores during low clinical disease activity were not associated with a higher risk of relapse. According to Galli, this finding is not well understood and needs to be unravelled in future research.
- Galli E, et al. The role of positron emission tomography/computed tomography (PET/CT) in disease activity assessment in patients with large vessel vasculitis. OP0069, EULAR 2021 Virtual Congress, 2-5 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Mavrilimumab outperforms placebo in severe COVID-19 Next Article
Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis »
« Mavrilimumab outperforms placebo in severe COVID-19 Next Article
Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis »
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy